Lista de obras -

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis

artículo científico publicado en 2011

Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS).

artículo científico publicado en 2009

Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial.

artículo científico publicado en 2011

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

artículo científico publicado en 2010

Dual energy x-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database

artículo científico publicado en 2006

Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.

artículo científico publicado en 2014

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

artículo científico publicado en 2012

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

artículo científico publicado en 2012

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

artículo científico publicado en 2009

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

artículo científico publicado en 2008

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older

artículo científico publicado en 2010

Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial.

artículo científico publicado en 2009

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

article

Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men.

artículo científico publicado en 2004

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

artículo científico publicado en 2005

Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club

artículo científico publicado en 2005

Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.

artículo científico publicado en 2009

Fracture risk and zoledronic acid therapy in men with osteoporosis

artículo científico publicado en 2012

Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium

artículo científico publicado en 2014

Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on Male Osteoporosis (NEMO) study

artículo científico publicado en 2008

Health technology assessment in osteoporosis

artículo científico publicado en 2013

Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT.

artículo científico publicado en 2011

Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS).

artículo científico publicado en 2013

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial

artículo científico publicado en 2011

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

artículo científico publicado en 2007

Quality of life in sarcopenia and frailty

artículo científico publicado en 2013

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

artículo científico publicado en 2014

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

artículo científico publicado en 2012

Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study

artículo científico publicado en 2015

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

artículo científico publicado en 2012

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

artículo científico publicado en 2013

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

artículo científico publicado en 2004

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study

artículo científico publicado en 2011

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

artículo científico publicado en 2006

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

artículo científico publicado en 2012

Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis

artículo científico publicado en 2012

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data

artículo científico publicado en 2005

Lista de obras de

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis

Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS).

Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Dual energy x-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database

Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older

Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial.

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men.

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club

Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.

Fracture risk and zoledronic acid therapy in men with osteoporosis

Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium

Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on Male Osteoporosis (NEMO) study

Health technology assessment in osteoporosis

Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT.

Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS).

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

Quality of life in sarcopenia and frailty

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data